Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369785 · ClinicalTrials.gov registry record · Phase 3
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 198
- Enrollment target
NCT00369785 is a Phase 3 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 198 participants.
The verdict
NCT00369785, a Phase 3 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 198 participants
- Enrollment target
Study Summary
RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors. It is not yet known whether donepezil is more effective than a placebo in lessening side effects of radiation therapy in patients with brain tumors. PURPOSE: This randomized phase III trial is studying donepezil to see how well it works in lessening side effects of radiation therapy compared with a placebo in patients who have undergone radiation therapy for brain tumors.
Interventions
- DRUG Placebo
- DRUG donepezil hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369785
The ClinicalTrials.gov registry entry for NCT00369785 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00369785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369785 about?
NCT00369785 is a clinical study titled "Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors". RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of life in patients who have undergone radiation therapy for brain tumors. It is not yet known whether donepezil is more effective than a placebo in lessening side effects of radiation therapy in patients with br...
What is the current status of trial NCT00369785?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 198 participants. The study started on 2008-02. Estimated completion is 2012-07-01.
What interventions are being tested in trial NCT00369785?
The interventions under investigation include: Placebo (DRUG), donepezil hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00369785?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.